These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30012772)

  • 1. Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
    Barrett SE; Teller RS; Forster SP; Li L; Mackey MA; Skomski D; Yang Z; Fillgrove KL; Doto GJ; Wood SL; Lebron J; Grobler JA; Sanchez RI; Liu Z; Lu B; Niu T; Sun L; Gindy ME
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
    Markowitz M; Grobler JA
    Curr Opin HIV AIDS; 2020 Jan; 15(1):27-32. PubMed ID: 31658118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.
    Markowitz M; Sarafianos SG
    Curr Opin HIV AIDS; 2018 Jul; 13(4):294-299. PubMed ID: 29697468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.
    Stoddart CA; Galkina SA; Joshi P; Kosikova G; Moreno ME; Rivera JM; Sloan B; Reeve AB; Sarafianos SG; Murphey-Corb M; Parniak MA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4190-8. PubMed ID: 25941222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.
    Takamatsu Y; Das D; Kohgo S; Hayashi H; Delino NS; Sarafianos SG; Mitsuya H; Maeda K
    Cell Chem Biol; 2018 Oct; 25(10):1268-1278.e3. PubMed ID: 30174310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
    Wu VH; Smith RA; Masoum S; Raugi DN; Ba S; Seydi M; Grobler JA; Gottlieb GS;
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.
    Gulick RM
    Top Antivir Med; 2018 Apr; 25(4):127-132. PubMed ID: 29689540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3.
    Markowitz M; Gettie A; St Bernard L; Andrews CD; Mohri H; Horowitz A; Grasperge BF; Blanchard JL; Niu T; Sun L; Fillgrove K; Hazuda DJ; Grobler JA
    J Infect Dis; 2020 Apr; 221(9):1398-1406. PubMed ID: 31175822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
    Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
    Flexner C; Owen A; Siccardi M; Swindells S
    Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
    Matthews RP; Patel M; Barrett SE; Haspeslagh L; Reynders T; Zhang S; Rottey S; Goodey A; Vargo RC; Grobler JA; Stoch SA; Iwamoto M
    Nat Med; 2021 Oct; 27(10):1712-1717. PubMed ID: 34608329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.
    Jacobson JM; Flexner CW
    Curr Opin HIV AIDS; 2017 Jul; 12(4):343-350. PubMed ID: 28368868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates.
    Pons-Faudoa FP; Di Trani N; Capuani S; Campa-Carranza JN; Nehete B; Sharma S; Shelton KA; Bushman LR; Abdelmawla F; Williams M; Roon L; Nerguizian D; Chua CYX; Ittmann MM; Nichols JE; Kimata JT; Anderson PL; Nehete PN; Arduino RC; Grattoni A
    Sci Transl Med; 2023 Jun; 15(702):eadg2887. PubMed ID: 37379369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA.
    Shanmugasundaram U; Kovarova M; Ho PT; Schramm N; Wahl A; Parniak MA; Garcia JV
    PLoS One; 2016; 11(7):e0159517. PubMed ID: 27438728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
    Kawamoto A; Kodama E; Sarafianos SG; Sakagami Y; Kohgo S; Kitano K; Ashida N; Iwai Y; Hayakawa H; Nakata H; Mitsuya H; Arnold E; Matsuoka M
    Int J Biochem Cell Biol; 2008; 40(11):2410-20. PubMed ID: 18487070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine).
    Alexandre FR; Rahali R; Rahali H; Guillon S; Convard T; Fillgrove K; Lai MT; Meillon JC; Xu M; Small J; Dousson CB; Raheem IT
    J Med Chem; 2018 Oct; 61(20):9218-9228. PubMed ID: 30265808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular islatravir pharmacology differs between species in an in vitro model: implications for preclinical study design.
    Sykes C; Van Horne B; Jones J; Kashuba ADM; Gatto G; Van Der Straten A; Johnson L; Cottrell ML
    J Antimicrob Chemother; 2022 Mar; 77(4):1000-1004. PubMed ID: 35134162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
    Hattori S; Ide K; Nakata H; Harada H; Suzu S; Ashida N; Kohgo S; Hayakawa H; Mitsuya H; Okada S
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3887-93. PubMed ID: 19546363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection.
    Matthews RP; Zang X; Barrett SE; Koynov A; Goodey A; Heimbach T; Weissler VL; Leyssens C; Reynders T; Xu Z; Rottey S; Vargo R; Robertson MN; Stoch SA; Iwamoto M
    J Acquir Immune Defic Syndr; 2023 Apr; 92(4):310-316. PubMed ID: 36450129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.